What changed in Incyte Corporation's latest annual report
In the year ended 31 Dec 2025, Incyte Corporation's revenue rose 21.2% to USD 5.14bn, from USD 4.24bn; net income rose 3845% to USD 1.29bn, from USD 32.62m; cash and cash equivalents rose 83.5% to USD 3.10bn, from USD 1.69bn.
Year ended 31 Dec 2025. Source: 10-K filed 10 Feb 2026, read it on SEC EDGAR.
USD 4.24bn to USD 5.14bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.24bn | 5.14bn | Up 21.2% |
| Net income | 32.62m | 1.29bn | Up 3845% |
| Total assets | 5.44bn | 6.96bn | Up 27.8% |
| Total liabilities | 2.00bn | 1.79bn | Down 10.3% |
| Cash and cash equivalents | 1.69bn | 3.10bn | Up 83.5% |
| Shareholders' equity | 3.45bn | 5.17bn | Up 49.9% |
Questions people ask
Did Incyte Corporation's revenue grow last year?
Revenue grew 21.2%, from USD 4.24bn to USD 5.14bn in the year ended 31 Dec 2025.
Is Incyte Corporation profitable?
Yes. Net income was USD 1.29bn in the year ended 31 Dec 2025. The year before: USD 32.62m.
How much cash and debt does Incyte Corporation have?
At its latest year end (31 Dec 2025), Incyte Corporation reported cash and cash equivalents of USD 3.10bn.
Where do these numbers come from?
From Incyte Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Incyte Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc.Cash and cash equivalents up 16.3%
- Medpace Holdings, Inc.Shareholders' equity down 44.4%
- Charles River Laboratories International, Inc.Cash and cash equivalents up 9.8%
- ICON plcNet income down 69%